LENZ Therapeutics Inc. (LENZ)
21.25
-1.75 (-7.61%)
At close: Apr 04, 2025, 3:47 PM
-7.61% (1D)
| Bid | 21.18 |
| Market Cap | 585.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -2.34 |
| PE Ratio (ttm) | -9.08 |
| Forward PE | -14.63 |
| Analyst | Buy |
| Ask | 21.35 |
| Volume | 461,797 |
| Avg. Volume (20D) | 180,373 |
| Open | 21.75 |
| Previous Close | 23.00 |
| Day's Range | 20.08 - 22.02 |
| 52-Week Range | 14.42 - 38.93 |
| Beta | 0.42 |
About LENZ
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California....
Industry Biotechnology
Sector Healthcare
IPO Date Mar 22, 2024
Employees 6
Stock Exchange NASDAQ
Ticker Symbol LENZ
Website https://www.lenz-tx.com
Analyst Forecast
According to 6 analyst ratings, the average rating for LENZ stock is "Buy." The 12-month stock price forecast is $37, which is an increase of 74.12% from the latest price.
Stock Forecasts5 months ago
+5.48%
LENZ Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
5 months ago
-2.86%
LENZ Therapeutics shares are trading higher after the company announced the FDA accepted its new drug application for LNZ100 for the treatment of Presbyopia.
